Find your next paid study

Incyte CorporationNCT06615050

~$50 – $2,100

Actual pay is set by the research site.

Use of Granulocyte Colony Stimulating Factor (G-CSF) Mobilized Leukapheresis Collections From Healthy Volunteers to Develop Improved Methods of Stem Cell and Lymphocyte Selection for Allogeneic Transplantation

Bone marrow transplants (BMT) are one form of treatment for disorders of the blood, including leukemia. However, because the procedure is often associated with…

Graft-Versus-Host DiseaseGraft-versus-leukemiaDonor Apheresis

National Heart, Lung, and Blood Institute (NHLBI)NCT00001529

~$10 – $675

Actual pay is set by the research site.

Graft-Versus-Host DiseaseGVHDUndefined

A Multi-Center, Phase II, Randomized Double-Blind Trial to Evaluate the Efficacy and Safety of Photobiomodulation for the Treatment of Oral Chronic Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation (the LIGHT Trial)

The purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral …

Memorial Sloan Kettering Cancer CenterNCT05675930

Actual pay is set by the research site.

Observational

Pilot Trial of Non-invasive Electrostimulation in Chronic Ocular Graft-vs-Host Disease

This trial is testing to see if electrostimulation treatment (ET) will be effective in treating those with ocular Graft vs. Host Disease.

Chronic Ocular Graft-versus-host Disease

Zhonghui K. Luo, MD, PhDNCT07166848

~$10 – $1,125

Actual pay is set by the research site.

Phase 1

A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) Following Allogenic Hematopoietic Stem Cell Transplantation (HSCT)

This is a phase I-II clinical trial. Adult subjects with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allel…

Graft-versus-host Disease

Northwell HealthNCT05289167

~$150 – $4,500

Actual pay is set by the research site.

Hematological MalignanciesGraft-versus-Host Disease (GVHD)

A Phase II Randomized Trial to Optimize GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation in Older Adults With Hematological Malignancies: the PROMISE Trial

This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide…

University of NebraskaNCT06799195

Actual pay is set by the research site.

Observational

Multi-Site Randomized Controlled Trial of A Multidisciplinary Intervention for Adults With Chronic Graft Versus Host Disease

The goal of this study is to demonstrate the efficacy of a multidisciplinary group-based telehealth intervention (HORIZONS) compared to minimally enhanced usua…

Bone Marrow Transplant ComplicationsGraft-versus-Host Disease

Massachusetts General HospitalNCT06910969

~$10 – $750

Actual pay is set by the research site.

Phase 1

A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-versus-Host Disease (GvHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Phase I-II studying post transplant cyclophosphamide, bortezomib and sitagliptin for GvHD prevention in allogeneic HSCT. Adults with hematologic malignancies u…

GVHD - Graft-Versus-Host Disease

Northwell HealthNCT07675174

~$150 – $4,500

Actual pay is set by the research site.

Chronic Graft-versus-host Disease (cGVHD)

Phase II Randomized Study of Ruxolitinib vs Prednisone as First-Line Therapy for Chronic Graft vs Host Disease Needing Systemic Therapy

Allogeneic transplant is potentially curative for hematological malignancies but its use is limited by the development of GVHD. Ruxolitinib now has FDA approva…

H. Lee Moffitt Cancer Center and Research InstituteNCT06660355

Actual pay is set by the research site.

Graft-versus-Host Disease (GVHD)Hematologic MalignanciesAllogeneic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) With Low-Dose Post-Transplant Cyclophosphamide for Prophylaxis of Graft-versus-Host Disease in Hematological Malignancies

This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophyla…

Milton S. Hershey Medical CenterNCT06926595

Actual pay is set by the research site.

Acute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndromes+5 more

Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies

The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and yo…

Memorial Sloan Kettering Cancer CenterNCT07566377

Actual pay is set by the research site.

Chronic Graft-Versus-Host Disease (cGVHD)

A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy

The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Partici…